Osteoporosis International

, Volume 14, Issue 12, pp 1028–1034

The fracture liaison service: success of a program for the evaluation and management of patients with osteoporotic fracture

  • Alastair R. McLellan
  • Stephen J. Gallacher
  • Mayrine Fraser
  • Carol McQuillian
Original Article

Abstract

Introduction: Fracture care often represents the first opportunity for clinical management of osteoporosis; however, many patients do not receive any evaluation after a fracture. In Glasgow, Scotland, fewer than 10% of fracture patients underwent bone mineral density (BMD) testing. In an effort to better meet the needs of fracture patients by providing routine assessment and, where necessary, treatment for osteoporosis after their fracture, a novel service (The Fracture Liaison Service) was designed and implemented in two separate National Health Service trusts in Glasgow. Methods: An agreed-upon standard of care for men and women 50+ years of age with fractures was established in collaboration with orthopedic surgeons and primary care physicians. The Fracture Liaison Service assumes responsibility for fracture case-finding and for assessing and performing diagnostic evaluations (including axial DXA), and making specific treatment recommendations for the secondary prevention of osteoporotic fractures. Results: During the first 18 months of operation, more than 4,600 patients with fractures of the hip, wrist, humerus, ankle, foot, hand, and other sites were seen by the Fracture Liaison Service’s osteoporosis specialist nurses. Nearly three quarters of these patients were considered for BMD testing; treatment was recommended for approximately 20% of the patients without need for BMD testing. Overall, 82.3% of patients who had BMD testing were found to be osteopenic or osteoporotic at the hip or spine. Conclusions: The Fracture Liaison Service has successfully identified and evaluated most patients with fractures. Only those patients who declined were not evaluated. The ultimate success of the program will be measured by the subsequent fracture experience of these patients, but clear improvements in diagnosing and treating low bone mineral density in patients with fracture have already been demonstrated.

Keywords

Clinic Fracture Osteoporosis Program Risk Assessment Secondary prevention 

References

  1. 1.
    Cummings SR, Black DM, Rubin SM (1989) Lifetime risks of hip, Colles’, or vertebral fracture and coronary heart disease among white postmenopausal women. Arch Intern Med 149:2445–2448PubMedGoogle Scholar
  2. 2.
    Lauritzen JB, Schwarz P, Lund B, McNair P, Transbol I (1993) Changing incidence and residual lifetime risk of common osteoporosis-related fractures. Osteoporos Int 3:127–132PubMedGoogle Scholar
  3. 3.
    Ross PD (1996) Osteoporosis: frequency, consequences, and risk factors. Arch Intern Med 156:1399–1411PubMedGoogle Scholar
  4. 4.
    National Osteoporosis Foundation (1998) Osteoporosis: review of the evidence for prevention, diagnosis, and treatment and cost-effectiveness analysis. Osteoporos Int 8[Suppl 4]:S1–S88Google Scholar
  5. 5.
    Melton LJIII, Atkinson EJ, O’Connor MK, O’Fallon MK, Riggs BL (1998) Bone density and fracture risk in men. J Bone Miner Res 13:1915–1923PubMedGoogle Scholar
  6. 6.
    Working Party Writing Group (2001) Osteoporosis: clinical guidelines for prevention and treatment. Update on pharmacological interventions and an algorithm for management. Royal College of Physicians, London pp 1–14Google Scholar
  7. 7.
    Dolan P, Torgerson DJ (1998) The cost of treating osteoporotic fractures in the United Kingdom female population. Osteoporos Int 8:611–617PubMedGoogle Scholar
  8. 8.
    Klotzbuecher C, Ross P, Landsman P, Abbott T, Berger M (2000) Patients with prior fractures have an increased risk of future fractures: a summary of the literature and statistical synthesis. J Bone Miner Res 15:721–739PubMedGoogle Scholar
  9. 9.
    Sambrook PN, Seeman E, Phillips SR, Ebeling PR (2002) Preventing osteoporosis: outcomes of the Australian Fracture Prevention Summit. Med J Aust 176[Suppl]:S1–S16Google Scholar
  10. 10.
    Pal B (1999) Questionnaire survey of advice given to patients with fractures. BMJ 318:500–501PubMedGoogle Scholar
  11. 11.
    Torgerson DJ, Dolan P (1999) Drug treatments that reduce fracture rate are underused after vertebral fractures. BMJ 318:1698Google Scholar
  12. 12.
    Simpson L (1999) Advice given on osteoporosis (Electronic letter). BMJGoogle Scholar
  13. 13.
    Dolan AL (1999) Audit of awareness and diagnosis of osteoporosis in Colles fracture (Electronic letter). BMJGoogle Scholar
  14. 14.
    Hajcsar EE, Hawker G, Bogoch ER (2000) Investigation and treatment of osteoporosis in patients with fragility fractures. Can Med Assoc J 163:819–822Google Scholar
  15. 15.
    Khan SA, de Geus C, Holroyd B, Russell AS (2001) Osteoporosis follow-up after wrist fractures following minor trauma. Arch Intern Med 161:1309–1312CrossRefPubMedGoogle Scholar
  16. 16.
    Zochling JM, Schwarz JM, March L, Sambrook PN (2001) Is osteoporosis undertreated after minimal trauma fracture? Med J Aust 174:663–664PubMedGoogle Scholar
  17. 17.
    Wilkinson TJ, Sainsbury R, Gilchrist NL (2001) Osteoporosis follow-up after fracture. Arch Intern Med 161:2633CrossRefGoogle Scholar
  18. 18.
    Versluis RGJA, Papapoulos SE (2002) Osteoporosis in general practice: failure to link fractures to the diagnosis osteoporosis Osteoporos Int 13[Suppl 1]:S85 (Abstract)Google Scholar
  19. 19.
    Kanterewicz E, Yanez A (2001) Osteoporosis attitudes after a Colles fracture. Arch Intern Med 161:2633–2634CrossRefGoogle Scholar
  20. 20.
    Onder G, Pedone C, Gambassi G, Landi F, Cesari M, Bernabei R (2001) Treatment of osteoporosis among older adults discharged from hospital in Italy. Eur J Clin Pharmacol 57:599–604PubMedGoogle Scholar
  21. 21.
    Castel H, Bonneh DY, Sherf M, Liel Y (2001) Awareness of osteoporosis and compliance with management guidelines in patients with newly diagnosed low-impact fractures. Osteoporos Int 12:559–564CrossRefPubMedGoogle Scholar
  22. 22.
    Cuddihy M-T, Gabriel SE, Crowson CS, Atkinson EJ, Tabini C, O’Fallon WM et al (2002) Osteoporosis intervention following distal forearm fractures: a missed opportunity? Arch Intern Med 162:421–426CrossRefPubMedGoogle Scholar
  23. 23.
    Freedman KB, Kaplan FS, Bilker WB, Strom BL, Lowe RA (2000) Treatment of osteoporosis: are physicians missing an opportunity? J Bone Joint Surg 82-A:1063–1070Google Scholar
  24. 24.
    McLellan AR, Fraser M (2002) A 28 month audit of the efficacy of the Fracture Liaison Service in offering secondary prevention for patients with osteoporotic fractures J Bone Miner Res 17[Suppl 1]:S358 (Abstract SU295)Google Scholar
  25. 25.
    Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC et al (1996) Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 348:1535–1541PubMedGoogle Scholar
  26. 26.
    Cummings SR, Black DM, Thompson DE, Applegate WB, Barrett-Connor E, Musliner TA et al (1998) Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 280:2077–2082PubMedGoogle Scholar
  27. 27.
    Pols HA, Felsenberg D, Hanley DA, Stepan J, Munoz-Torres M, Wilkin TJ et al (1999) Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: results of the FOSIT study. Foxamax International Trial Study Group. Osteoporos Int 9:461–468CrossRefPubMedGoogle Scholar
  28. 28.
    Reginster J, Minne HW, Sorensen OH, Hooper M, Roux C, Brandi Ml et al (2000) Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int 11:83–91PubMedGoogle Scholar
  29. 29.
    Harris ST, Watts NB, Genant HK, McKeever CD, Hangartner T, Keller M et al (1999) Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA 282:1344–1352PubMedGoogle Scholar
  30. 30.
    McClung MR, Geusens P, Miller PD, Zippel H, Bensen WG, Roux C et al (2001) Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med 344:333–340CrossRefPubMedGoogle Scholar
  31. 31.
    Scottish Intercollegiate Guidelines Network (2003) Management of osteoporosis. SIGN publication 71. SIGN, EdinburghGoogle Scholar
  32. 32.
    Hodkinson HM (1972) Evaluation of a mental test score for assessment of mental impairment in the elderly. Age Ageing 1:233–238PubMedGoogle Scholar
  33. 33.
    World Health Organization (1994) Assessment of fracture risk and application to screening for postmenopausal osteoporosis. WHO Technical Report Series. WHO, GenevaGoogle Scholar
  34. 34.
    Simonelli C, Killeen K, Mehle S, Swanson L (2002) Barriers to osteoporosis identification and treatment among primary care physicians and orthopedic surgeons. Mayo Clinic Proc 77:334–338Google Scholar
  35. 35.
    Jaglal SB, Hawker GA, Carroll J, McIsaac WJ, Jaakkimainen L, Cadarette SM et al (2001) Information needs of family physicians for the management of osteoporosis. J Bone Miner Res 16[Suppl 1]:S290 (Abstract)Google Scholar

Copyright information

© International Osteoporosis Foundation and National Osteoporosis Foundation 2003

Authors and Affiliations

  • Alastair R. McLellan
    • 1
    • 3
  • Stephen J. Gallacher
    • 2
  • Mayrine Fraser
    • 1
  • Carol McQuillian
    • 2
  1. 1.Western InfirmaryGlasgowUK
  2. 2.Southern General HospitalGlasgowUK
  3. 3.Division of Cardiovascular Sciences & MedicineWestern InfirmaryGlasgowUK

Personalised recommendations